TCR2 Therapeutics Inc. IPO Research Information

TCR2 Therapeutics Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on TCR2 Therapeutics Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
TCR2 Therapeutics Inc.	TCRR - NASDAQ	$14.00-$16.00	$15.00	$15.15	5 million	2/14/2019
Underwriter(s): Jefferies, SVB Leerink, BMO Capital
Co-Manager(s): Wedbush Capital, China Renaissance
Industry: Health Care
Filing(s): FIled 2018-12-28 Terms Added 2019-02-01

TCR2 Therapeutics Inc. Quote & Chart - Click for current quote - TCRR

About TCR2 Therapeutics Inc. (adapted from TCR2 Therapeutics Inc. prospectus):
They are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "TCRR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.